Skip to main content

Schroder ISF Healthcare Innovation

Schroder ISF Healthcare Innovation is an equity fund managed by Schroders in the Sektor – Helse category.

About this fund

Categorised as Sektor – Helse, Schroder ISF Healthcare Innovation is an equity fund from Schroders.

On return so far this year measured in NOK as of 13.11.2026, it places 13 of 18 funds in the group.

Launched in 2019, it has 7 years behind it.

The manager states a volatility of 13.6% for the fund.

The reference index is MSCI ACWI NR.

Manager
Schroders
Category
Sektor – Helse
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
LU1983299246
Inception
2019-07-31
Benchmark
MSCI ACWI NR
AUM
208 m EUR
Returns
YTD 4.0% · 1Y 8.2% · 3Y 5.8% · 5Y 3.7%

Portfolio managers

Formerly: Schroder ISF Hlthcr Innovt (Other)
Actively managedEquityGlobalHealth care
YTD Return · NOK
+4,0 %from NAV
The class started 31.07.2019. 10 years does not exist yet; the figure above is since launch, annualised (as of 16.11.2026).
Calculated NOK return from USD · A (NOK Calculated)

Computed from NAV history (to 16 Nov 2026)

Last NAV 126,28 EUR · 16 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+4,0 %
YTD
+8,2 %
1y
+5,8 %
3y, annualised
+3,7 %
5y, annualised
Fund size
208,4 mill. EUR
Total fund AUM
Management fee
1,50 %
Annual · 3 share classes
Ongoing charge
1,86 %
Annual · class A USD
Performance fee
None
Stated by the manager
Annual cost on platforms
1,43 %
Class A EUR · 2 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Jul 2019
ISIN LU2191243257
BenchmarkMSCI ACWI · Net
Fund website
Risk
Volatility (stated by the manager)13,6 %
Sharpe Ratio0,48
Beta0,48
Info Ratio−0,84
About the fund
The fund

Schroder ISF Healthcare Innovation has a history going back to 2020. The management company, Schroders, is an active asset manager covering equities, fixed income and private markets, with roots back to 1804 and headquarters in London. The company has been 100% controlled by Nuveen, part of the TIAA group, since the acquisition on 1 October 2026.

Investment philosophy

The fund invests in health care and medical-related companies worldwide that meet the manager's sustainability criteria. Its reference is a broad global equity index, not a health care index.

The managers

The fund is managed by one person, John Bowler in London. He is a global sector specialist for health care at Schroders, which he joined in 2003, and is listed as manager since 2019. He previously worked in healthcare research at AXA Investment Managers and at State Street Research. He holds a PhD in biochemistry and physiology from the University of Manchester.

The portfolio

The portfolio has more positions than comparable funds and has been less volatile. The lasting top positions are large pharmaceutical and health care companies such as Johnson & Johnson, AstraZeneca, Eli Lilly and UnitedHealth Group.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

JO
Portfolio Manager
On the fund since Jul 31, 2019

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#13/ 18Year to date
+3.98% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#16/ 221 year
+8.23% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#16/ 223 years (ann.)
+5.76% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#17/ 225 years (ann.)
+3.73% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data